Nektar Therapeutics provided revenue guidance for the full year 2022. The company announced that GAAP revenue is expected to be between $185 million and $195 million in 2022, including the $100 million of BMS collaboration milestones related to BEMPEG regulatory filings.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.235 USD | -1.98% | -24.39% | +119.47% |
05-09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
05-09 | Nektar Therapeutics Reiterates Earnings Guidance for the Year 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.47% | 232M | |
+39.93% | 734B | |
+32.83% | 591B | |
-6.02% | 350B | |
+14.99% | 315B | |
+1.50% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+5.59% | 161B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022